Recurrent Squamous Cell Lung Carcinoma Active Not Recruiting Phase 2 Trials for Taselisib (DB12108)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs